So is the CDx thinking that Jannsen will eventually run a trial to see if they use PromarkerD to determine dosing for patients newly initiating canaglifozin? Otherwise I don’t really see the value of the study other than it shows that canaglifozin works. What is the actual clinical utility here?
So is the CDx thinking that Jannsen will eventually run a trial...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.000(0.00%) |
Mkt cap ! $132.3M | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.06 | $1.00 | $126.3K | 124.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4882 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 7500 | 2 |
View Market Depth
| Last trade - 15.41pm 12/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |